UP!
|
Type
|
Public |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 2010 in Waltham, Massachusetts |
| Products | Varubi |
|
Number of employees
|
286 (2016) |
| Website | www |
Tesaro is a public pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.
Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Nirabarib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.
| 2016-07-05 | Boost Price Target | Mizuho | Buy | $67.00 to $94.00 |
| 2016-07-01 | Boost Price Target | Citigroup Inc. | Buy | $65.00 to $90.00 |
| 2016-06-30 | Reiterated Rating | Wedbush | Buy | |
| 2016-06-30 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo | Outperform | |
| 2016-06-30 | Reiterated Rating | Mizuho | Outperform | $67.00 |
| 2016-06-30 | Boost Price Target | Leerink Swann | Outperform | $65.00 to $95.00 |
| 2016-06-30 | Downgrade | Jefferies Group | Buy to Hold | $53.00 to $75.00 |
| 2016-06-30 | Reiterated Rating | FBR & Co | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo & Co. | Outperform | |
| 2016-06-29 | Boost Price Target | FBR & Co. | Outperform | $65.00 to $93.00 |
| 2016-06-06 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-06 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-05-19 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-05-14 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-05-14 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-13 | Initiated Coverage | Credit Suisse | Outperform | $56.00 |
| 2016-05-08 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-05-06 | Reiterated Rating | FBR & Co. | Buy | $65.00 |
| 2016-04-13 | Initiated Coverage | FBR & Co. | Outperform | $65.00 |
| 2016-04-11 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-04-06 | Reiterated Rating | Mizuho | Buy | $67.00 |
| 2016-04-06 | Reiterated Rating | Wedbush | Outperform | $72.00 |
| 2016-03-31 | Reiterated Rating | Jefferies Group | Buy | |
| 2016-03-17 | Reiterated Rating | Citigroup Inc. | Buy | $65.00 |
| 2016-03-16 | Reiterated Rating | Wedbush | Outperform | $72.00 |
| 2016-03-14 | Reiterated Rating | Leerink Swann | Outperform | $69.00 |
| 2016-03-01 | Initiated Coverage | SunTrust | Buy | $60.00 |
| 2016-03-01 | Initiated Coverage | SunTrust Banks Inc. | Buy | $60.00 |
| 2016-02-26 | Lower Price Target | Jefferies Group | Buy | $58.00 to $55.00 |
| 2016-02-05 | Initiated Coverage | Lake Street Capital | Buy | $61.00 |
| 2016-01-20 | Initiated Coverage | Wedbush | Outperform | $72.00 |
| 2015-12-03 | Initiated Coverage | Wells Fargo | Outperform | |
| 2015-10-16 | Reiterated Rating | Leerink Swann | Buy | |
| 2015-09-02 | Reiterated Rating | Mizuho | Buy | $67.00 |
| 2015-08-31 | Initiated Coverage | Raymond James | Strong-Buy | $70.00 |
| 2015-08-31 | Initiated Coverage | Raymond James Financial Inc. | Strong-Buy | $70.00 |
| 2015-08-24 | Initiated Coverage | Leerink Swann | Outperform | $69.00 |
| 2015-07-02 | Reiterated Rating | Mizuho | Buy | |
| 2015-06-01 | Reiterated Rating | Mizuho | Buy | $65.00 to $67.00 |
| 2015-04-16 | Boost Price Target | Jefferies Group | Buy | $49.00 to $70.00 |
| 2015-04-01 | Boost Price Target | Mizuho | Buy | $50.00 to $65.00 |
| 2015-02-23 | Boost Price Target | Citigroup Inc. | Focus List to Buy | $51.00 to $79.00 |
| 2015-02-20 | Boost Price Target | Mizuho | Buy | $44.00 to $50.00 |
| 2014-10-07 | Initiated Coverage | Jefferies Group | Buy | $40.00 |
| 2014-10-02 | Initiated Coverage | Guggenheim | Buy | $46.00 |
| 2014-06-02 | Reiterated Rating | Mizuho | Positive | $44.00 |
| 2014-05-12 | Boost Price Target | BMO Capital Markets | $46.00 to $66.00 | |
| 2014-03-28 | Edison Investment Research | Positive | ||
| 2014-03-18 | Initiated Coverage | Edison Investment Research | Neutral to Positive | |
| 2014-03-14 | Boost Price Target | Citigroup Inc. | Buy | $42.00 to $51.00 |
| 2014-03-13 | Boost Price Target | Deutsche Bank | $72.00 | |
| 2014-02-04 | Downgrade | Morgan Stanley | Overweight to Equal Weight | $45.00 to $30.00 |
| 2014-01-21 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $36.00 to $46.00 |
| 2014-01-14 | Reiterated Rating | Deutsche Bank | Buy | $62.00 |
| 2013-12-23 | Lower Price Target | Deutsche Bank | $62.00 | |
| 2012-07-23 | Initiated | Robert W. Baird | Outperform | $19 |
| 2016-07-05 | Boost Price Target | Mizuho | Buy | $67.00 to $94.00 |
| 2016-07-01 | Boost Price Target | Citigroup Inc. | Buy | $65.00 to $90.00 |
| 2016-06-30 | Reiterated Rating | Wedbush | Buy | |
| 2016-06-30 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-30 | Reiterated Rating | Wells Fargo | Outperform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In TSRO 23 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| BlackRock Fund Advisors | 1.72M |
| BlackRock Institutional Trust Company, N.A. | 0.83M |
| JANUS CAPITAL MANAGEMENT LLC | 0.63M |
| BLACKROCK ADVISORS LLC | 0.47M |
| RUSSELL FRANK CO/ | 0.28M |
| BlackRock Group LTD | 0.28M |
| BlackRock Investment Management, LLC | 0.13M |
| GLG LLC | 58563 |
| Iguana Healthcare Management, LLC | 45000 |
| Spot Trading L.L.C | 26486 |
| IRONBRIDGE CAPITAL MANAGEMENT LP | 22211 |
| GLG Partners LP | 20186 |
| KCG Holdings, Inc. | 16248 |
| PEAK6 Investments, L.P. | 13181 |
| March Altus Capital Management LP | 10000 |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| KRAMLICH C RICHARD | 31.90% (11499255) | CLVS / ECHO / HPTX / INWK / SIVB / TRGT / TSRO / XOOM / ZHNE / |
| KERINS PATRICK J | 26.86% (9681129) | ARDX / CLVS / CRCM / CVT / ECHO / ECOM / EPZM / HIVE / HPTX / LOXO / MM / ROKA / SNSS / SURF / SYBX / TSRO / |
| BARRETT M JAMES | 26.86% (9681129) | ADNC / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FOLD / GLYC / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZSAN / |
| NEW ENTERPRISE ASSOCIATES 13 LP | 26.86% (9681129) | CLVS / CRCM / CVT / EPZM / GLYC / HIVE / ROKA / TSRO / |
| INTERWEST PARTNERS X LP | 6.86% (2471701) | TSRO / |
| InterWest Management Partners X, LLC | 6.86% (2471701) | TSRO / |
| Khattar Jack A. President, CEO | 3.04% (1094000) | SUPN / TSRO / |
| MOULDER LEON O JR Chief Executive Officer | 2.87% (1034664) | CBST / TRVN / TSRO / |
| BASKETT FOREST | 2.05% (739516) | ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FIO / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TSRO / XOOM / |
| BARRIS PETER J | 2.05% (739516) | ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / GLYC / GRPN / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZHNE / |
| Viswanathan Ravi | 2.05% (739516) | ABIO / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / EPZM / HIVE / LOXO / ONTY / ROKA / SURF / SYBX / TSRO / |
| SANDELL SCOTT D | 2.05% (739516) | ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FIO / GLYC / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WDAY / WIFI / XOOM / |
| MOTT DAVID M | 2.05% (739516) | ABIO / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / EPZM / HIVE / LOXO / ONTY / ROKA / SURF / SYBX / TSRO / |
| KOLLURI KRISHNA KITTU | 1.97% (710429) | ADNC / AKAO / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / SUPN / TSRO / XOOM / |
| Weller Harry R | 1.97% (710429) | ARDX / CLVS / CRCM / CVT / EPZM / HIVE / LOXO / OPWR / ROKA / TSRO / |
| Rodgers Richard J Exec. Vice President & CFO | 0.71% (257141) | ARDX / RNN / TSRO / |
| Alleva Lawrence M | 0.08% (28303) | BFAM / TSRO / |
| Hedley Mary Lynne Pres.&Chief Scientific Officer | 0.04% (14998) | BLUE / RCPT / TSRO / |
| Huber Martin H. Jr. SVP & Chief Medical Officer | 0.03% (11327) | TSRO / |
| SEIDENBERG BETH C | 0.03% (10998) | ATRA / EPZM / TSRO / |
| Oliveira Orlando SVP & GM, International | 0.03% (9076) | TSRO / |
| Farmer Joseph L SVP, GC and Secretary | 0.02% (7854) | AMAG / TSRO / |
| PEARSON TIMOTHY R EVP, CFO | 0.02% (6211) | GLYC / TSRO / |
| Bogle Grant C. SVP & Chief Commercial Officer | 0.01% (4431) | TSRO / |
| Walker Paul Edward | 0.01% (4041) | TSRO / |
UM